{"nctId":"NCT02016560","briefTitle":"Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects","startDateStruct":{"date":"2013-12","type":"ACTUAL"},"conditions":["Alzheimer's Disease"],"count":383,"armGroups":[{"label":"Exploratory Cognitively Healthy Subjects","type":"EXPERIMENTAL","interventionNames":["Drug: florbetapir F 18","Drug: Flortaucipir F18","Procedure: Brain PET Scan"]},{"label":"Exploratory MCI Subjects","type":"EXPERIMENTAL","interventionNames":["Drug: florbetapir F 18","Drug: Flortaucipir F18","Procedure: Brain PET Scan"]},{"label":"Exploratory AD Subjects","type":"EXPERIMENTAL","interventionNames":["Drug: florbetapir F 18","Drug: Flortaucipir F18","Procedure: Brain PET Scan"]},{"label":"Confirmatory Subjects","type":"EXPERIMENTAL","interventionNames":["Drug: florbetapir F 18","Drug: Flortaucipir F18","Procedure: Brain PET Scan"]}],"interventions":[{"name":"florbetapir F 18","otherNames":["Amyvid","18F-AV-45"]},{"name":"Flortaucipir F18","otherNames":["T807","18F-AV-1451"]},{"name":"Brain PET Scan","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nExploratory Cognitively Healthy Subjects\n\n* ≥ 20 to ≤ 40 years of age OR ≥ 50 years of age\n* Mini-mental state examination (MMSE) ≥ 29\n* No significant history of cognitive impairment\n\nExploratory MCI Subjects\n\n* ≥ 50 years of age\n* MMSE ≥ 24\n* Have MCI consistent with National Institute on Aging-Alzheimer's Association (NIA-AA) working group's diagnostic guidelines for AD\n* Have a study partner that can report on subject's activities of daily living\n\nExploratory AD Subjects\n\n* ≥ 50 years of age\n* MMSE \\> 10\n* Have possible or probable AD based on the NIA-AA working group's diagnostic guidelines for AD\n* Have a study partner that can report on subject's activities of daily living\n\nConfirmatory Subjects\n\n* ≥ 50 years of age\n* MMSE ≥ 20 and ≤ 27\n* Cognitively impaired subjects with either MCI or dementia with a suspected neurodegenerative cause\n* Have a study partner that can report on subject's activities of daily living\n\nExclusion Criteria:\n\n* Current clinically significant psychiatric disease\n* Evidence of structural brain abnormalities\n* History of moderate or severe traumatic brain injury\n* Current clinically significant cardiovascular disease or ECG abnormalities, or additional risk factors for Torsades de Pointes\n* Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer\n* History of alcohol or substance abuse or dependence\n* Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception\n* Have received or participated in a trial with investigational medications in the past 30 days\n* Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session.","healthyVolunteers":true,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline","description":"Confirm the relationship between neocortical flortaucipir uptake and the subsequent rate of cognitive decline at longitudinal follow up that was observed in the Exploratory Phase of the study. Patients were assigned to groups by majority classification of the flortaucipir positron emission tomography (PET) scan by five independent imaging physicians. Clinically meaningful cognitive and functional deterioration was defined as a 1 point or greater worsening on clinical dementia rating - sum of boxes (CDR-SB) score over the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"31","spread":null}]},{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"PRIMARY","title":"Exploratory Phase: Cross-sectional Flortaucipir Imaging Results","description":"Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.53","spread":"0.037"},{"groupId":"OG001","value":"1.26","spread":"0.030"},{"groupId":"OG002","value":"1.08","spread":"0.093"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":"0.051"},{"groupId":"OG001","value":"0.99","spread":"0.029"},{"groupId":"OG002","value":"0.98","spread":"0.029"},{"groupId":"OG003","value":"1.01","spread":"0.039"}]}]}]},{"type":"PRIMARY","title":"Exploratory Phase: Longitudinal Change in Tau Deposition Over Time, by Amyloid Status","description":"Assess the rate of change of tau deposition as measured by flortaucipir uptake (SUVr) over time. Change = 18 months SUVr - baseline SUVr.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.052359","spread":"0.008536"},{"groupId":"OG001","value":"0.000655","spread":"0.002394"}]}]}]},{"type":"SECONDARY","title":"Confirmatory Phase: Diagnostic Performance of Flortaucipir Visual Read","description":"This analysis used dichotomized CDR-SB change as a truth standard (1 point or more worsening = true positive vs. less than 1 point worsening = true negative) to assess the diagnostic performance of baseline Advanced AD tau status (τAD++) as determined by flortaucipir scan interpretation. Sensitivity and Specificity were calculated for each of the 5 independent imaging readers. Sensitivity is the percentage of true positive cases correctly identified by an Advanced AD pattern scan. Specificity is the percentage of true negative cases correctly identified by scans that were not classified as Advanced AD pattern.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Exploratory Phase: Correlation Between Flortaucipir SUVr and Age","description":"Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0083","spread":"0.03905"},{"groupId":"OG001","value":"1.0203","spread":"0.03693"},{"groupId":"OG002","value":"1.0110","spread":"0.04149"},{"groupId":"OG003","value":"1.0010","spread":"0.02604"},{"groupId":"OG004","value":"1.0048","spread":"0.03978"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Injection site pain","Headache","Blood pressure increased","Injection site extravasation","Angina pectoris"]}}}